Articles tagged with Cancer Immunology
Scientists at Northwestern University have determined the three-dimensional structures of rye pollen's cancer-fighting molecules, secalosides A and B. This breakthrough opens the door to exploring how these molecules interact with the immune system and could inspire new approaches to cancer therapy.
The study reveals that low levels of CTDNEP1 drive early and deadly pancreatic tumors, highlighting its role as a tumor suppressor. Tumors with low CTDNEP1 expression showed stronger metabolic activity and immune evasion.
A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...
Researchers created an 'atlas' of immune cells in bone marrow cancer that provides insights into how the immune system interacts with cancerous plasma cells. The knowledge can improve survival predictions and guide treatment decisions for patients with multiple myeloma.
Researchers have developed a new way to boost the immune system's response to cancer by using specially engineered antibodies. The antibodies work by clustering multiple immune cell receptors, amplifying the signal that tells T cells to attack cancer cells.
A large-scale international study has deciphered a mechanism enabling breast cancer to metastasize to the brain. Researchers identified a specific chromosomal alteration predicting high likelihood of brain metastases and found that the absence of functional p53 gene impairs brain environment adaptation.
Researchers discovered a mechanism allowing melanoma cancer cells to paralyze immune cells by secreting extracellular vesicles, which can disrupt immune cell activity and even kill them. This breakthrough has promising therapeutic implications, enabling strengthening of immune cells and blocking molecules that enable vesicle adhesion.
Recent advances in immunotherapy have transformed multiple myeloma treatment, offering durable survival benefits. Emerging targets such as regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages are being explored to enhance treatment efficacy.
Researchers at MD Anderson Cancer Center have found that inhibiting GFER, a mitochondrial enzyme, in combination with immune checkpoint blockade improves antitumor response in preclinical models. This two-pronged approach holds promise for patients with pancreatic cancer.
Researchers at the University of Houston have discovered a potential therapeutic strategy for counteracting muscle wasting in pancreatic cancer by blocking a specific cell pathway. Muscle wasting, also known as cachexia, is a debilitating syndrome affecting 60-85% of patients with pancreatic cancer.
Dr Aldona Mzyk's project uses quantum sensors to track how immune cells interact with tumours, enabling the development of improved patient-tailored cancer therapies and earlier diagnosis tools. The research aims to overcome current cancer immunotherapies' failure in solid tumours by controlling metabolic changes.
The study found that the investigational vaccine produced an immune response in 74% of participants and was safe and well-tolerated. A Phase 2 study is planned to evaluate the vaccine's efficacy, offering new hope for triple-negative breast cancer treatment.
Researchers from City of Hope presented results on novel cellular and immunotherapies, treatment strategies for hard-to-treat blood cancers, and a first-in-human trial for GVHD. The studies showed promising outcomes, including higher event-free survival rates and fewer side effects.
Researchers found that CAR T cell therapy side effects, such as neurotoxicity and intestinal inflammation, are linked to high rates of death unrelated to cancer relapse. CirAEs were more common in patients who received cilta-cel and had higher non-relapse mortality rates.
Researchers found that patients who received immunochemotherapy before 3:00 pm experienced significantly longer progression-free survival and overall survival compared to those treated later. Earlier administration of immunotherapy was also associated with lower risks of cancer progression and death.
Researchers at MD Anderson have made significant discoveries in the treatment of rare bile duct cancers, with zanidatamab showing promising results. Additionally, a study identified RASH3D19 as a target to overcome treatment resistance in KRAS-mutant cancers.
The ESMO Immuno-Oncology Congress 2025 will discuss key developments in immuno-oncology, including combined approaches, AI in cancer therapy, and innovative strategies across various cancers. The congress aims to advance the field of immunotherapy and improve patient outcomes.
Researchers have discovered a pathway that makes estrogen receptor-positive breast cancer tumors responsive to immunotherapy. By inhibiting the estrogen receptor, LCOR molecule activation is enabled, allowing tumor cells to become visible to the immune system.
Researchers discovered breast cancer modifies lymphatic vessels to facilitate its spread. A specific protein, Matrix Gla protein (MPG), enables cancer cells to bind to lymphatic vessels, supporting metastasis. Understanding this process could lead to targeted therapies and improved patient outcomes.
Researchers have discovered that rhesus macaques shed TIGIT from immune cell surfaces when exposed to plasmin, a natural enzyme involved in blood clot breakdown. This creates a soluble form of TIGIT that can still bind anti-TIGIT monoclonal antibodies, potentially leading to misleading safety and efficacy data for human trials.
Researchers at LJI have discovered a cellular driver that leads to the development of tissue-resident memory T cells, which specialize in defending specific organs. The study found that GPR25 sustains TGF-\u00b2 signaling, promoting differentiation and transformation into these specialized immune cells.
A team of researchers led by Dr. Michele Ardolino is bridging scientific fields to unlock the mechanisms behind effective immune responses in cancer patients. They will study the interactions between the immune system, nervous system, and gut microbiome to design more personalized treatment strategies.
City of Hope experts will highlight advances in blood cancer research, cellular therapies, and precision medicine at the 2025 American Society of Hematology Annual Meeting and Exposition. The meeting will feature over 105 sessions covering topics such as CAR T cell therapy, transplant innovations, and precision medicine.
Researchers at Arizona State University discovered that SerpinB3 plays a natural role in the body's wound-healing process, helping skin recover after damage. The protein helps activate keratinocytes to rebuild tissue and improve skin strength.
Researchers found that bowel cancer cells can escape the immune system through epigenetic changes, leading to limited changes in how the cancer presents itself. This understanding could lead to targeted and effective treatments for patients with bowel cancer, particularly those who respond well to immunotherapy.
Researchers at Tokyo University of Science identified genes that predict CD8+ T cell expansion in cancer immunotherapy. A 'signature gene set' or 'expansion signature' was found to identify primed T cells for growth, predicting treatment response and offering a potential guide for new therapies.
Researchers found that combining zanzalintinib, a targeted therapy drug, with atezolizumab, an immune checkpoint inhibitor, improved survival rates by 20% compared to standard treatment regorafenib. The new combination also delayed cancer progression and showed promising results in patients with metastatic colorectal cancer.
UCLA investigators unveil decade-long survival data for immunotherapy in advanced lung cancer and promising results for novel therapies targeting PSMA, DKK1, and FGFR3 in various aggressive cancers. These breakthroughs hold promise for improved treatment outcomes and quality of life for patients with difficult-to-treat diseases.
A recent study found that patients with advanced lung and skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine. The observation marks a significant step toward a long-awaited universal cancer vaccine to boost tumor-fighting eff...
Researchers discovered craters on the surface of melanoma cells that serve as immune hubs and facilitate local tumor killing. These structures, termed CRATERs, may serve as a more accurate marker of immunotherapy's success in treating solid tumors.
Researchers at MD Anderson have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The study also identifies a new biomarker for improved immunotherapy responses in solid tumors.
A new combination therapy combining epigenetic therapy with anti-PD-1 antibody showed promising results in patients with relapsed or refractory natural killer/T-cell lymphoma. The treatment triggered viral mimicry, restoring immune sensitivity and improving survival rates.
Researchers at UMass Amherst have developed a nanoparticle-based vaccine that prevents melanoma, pancreatic and triple-negative breast cancer in mice. The vaccine achieved remarkable survival rates, with up to 88% of vaccinated mice remaining tumor-free.
The ASPIRE trial is a Phase III clinical study investigating whether adding chemotherapy to standard treatments can extend survival in men with advanced prostate cancer. The trial aims to determine the effectiveness of combining docetaxel with hormone therapy and apalutamide.
Research presents evidence suggesting that metabolically active visceral fat is associated with more advanced stages of endometrial cancer and lymph node metastases. The study found no strong correlation between visceral fat volume and its metabolic activity.
Researchers at Ohio State University have found that cancer immunotherapy fails due to a collapse in protein quality control, leading to T-cell exhaustion. This discovery offers a new avenue for cancer immune therapy development by targeting the protein production cycle.
Recent clinical trials demonstrate the potential benefits of neoadjuvant chemotherapy and immunotherapy in improving tumor response and surgical success for patients with locally advanced colon cancer. The approach also reduces the risk of recurrence and metastasis, increasing survival outcomes and decreasing cancer-related complications.
Researchers at CDI Lab have identified two protein transcription factors, Tcf1 and Lef1, as critical modulators of T cell fate in the thymus. This discovery could lead to novel approaches in treating immune deficiencies, autoimmune diseases, and optimizing immunotherapies in cancer treatment.
Researchers develop a new approach for treating inflammatory bowel diseases by delivering locked nucleic acids (LNAs) to the relevant organ using lipid nanoparticles. The study shows improvement in inflammation markers with no side effects, paving the way for potential treatments of rare genetic disorders and other diseases.
Research has shown that lymph nodes provide the right environment for stem-like T cells to survive, multiply, and produce killer cells. Preserving lymph nodes could strengthen immune responses and increase the effectiveness of immunotherapy. The study's findings have important implications for cancer therapy.
Researchers at UMass Amherst found that certain T-cells have an inherent ability to remember past viral foes, which could lead to next-generation cancer vaccines. This 'immunological memory' is crucial for the body's immune response and can be harnessed for targeted therapies.
This study reveals that GPNMB modifies the tumor microenvironment by repurposing macrophages into immunosuppressive tumor-associated macrophages. The interaction between GPNMB and Siglec-9 enables this reprogramming, leading to increased cancer cell motility and invasiveness.
Researchers developed a high-volume method to rapidly build and test large numbers of antibodies at once, accelerating antibody research and treatment development. The oPool+ display platform has potential applications in influenza vaccination research, infectious disease treatment, and cancer research.
Researchers have developed AlloCAR70-NKT, an innovative cell therapy harnessing the immune system to fight cancer. The therapy demonstrates a multi-pronged attack against kidney cancer, directly killing cells and disrupting the tumor's microenvironment.
A phase 2 clinical trial found that autologous tumor-infiltrating lymphocyte (TIL) cell therapy helped stabilize metastatic head and neck squamous cell carcinoma (HNSCC) in some patients. The median response duration was 7.6 months, with cancer stabilization occurring in 64% of patients.
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.
Researchers mapped the surface envelope glycoprotein of human endogenous retroviruses, opening doors to new diagnostic and therapeutic opportunities. The study revealed specific antibodies that target the viral proteins, potentially leading to new cancer immunotherapies and treatments for autoimmune diseases.
Researchers at the University of Chicago discovered that random fluctuations in gene expression enable certain cells to express genes from other tissues, promoting immune system training and tissue repair. This 'epigenetic noise' can also contribute to cancer development by allowing cancer cells to access a broader range of genes.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
Researchers found that pembrolizumab shrank or eliminated tumors in nearly 90% of participants with desmoplastic melanoma, a rare and aggressive skin cancer. The therapy offers a less invasive approach compared to surgery or radiation.
The Pew Charitable Trusts has announced the 2025 class of the Pew-Stewart Scholars Program for Cancer Research, supporting five early-career scientists in innovative research projects. The recipients will explore pressing topics such as complex cancer mechanisms and new drug targets.
A novel cancer vaccine has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies. The vaccine targets KRAS mutations found in about 25% of solid tumors and drives about 90% of pancreatic cancers and 50% of colorectal cancers.
A new multi-institutional study confirmed that the NSD2 protein can be targeted with a new drug, blocking it effectively reprogrammed DNA structure, reversed and prevented cancer growth in preclinical models of KRAS-mutant lung and pancreatic cancers. Targeting the brain-liver pathway with electronic wearables could prevent cancer-asso...
Researchers developed pH-responsive graphene-based nanocarriers that can target cancer cells, achieving efficient and safe drug delivery. The material's surface charge adapted to the acidic tumor environment, allowing it to bind and enter cancer cells while avoiding healthy tissues.
Researchers at La Jolla Institute for Immunology examine how genetics, sex hormones, and environmental factors shape the immune system. Women have a stronger immune response due to their XX chromosomes and estrogen, but also face an increased risk of autoimmune diseases.
Research suggests that consuming high levels of sucralose can make cancer treatment less effective by disrupting the gut microbiome and altering T cell function. However, adding arginine or citrulline supplements to the diet may restore immunotherapy effectiveness in patients with melanoma and non-small cell lung cancer.
Researchers at Chiba University have developed novel microfluidic devices that incorporate microcones to detect and characterize circulating tumor cells in blood. The devices demonstrated highly selective capture of human breast and lung cancer cells, with high efficiency even at high flow rates.
Researchers at Nagoya University have developed a new lipid nanoparticle that delivers mRNA five times more efficiently, allowing better delivery of genetic instructions to cells. The study showed significant improvements in mRNA delivery and effective suppression of tumor growth in mice.
Researchers developed a new AI model named BATMAN to improve T cell receptor therapy accuracy. The AI uses a vast database of over 22,000 TCR-peptide interactions to predict peptide binding and identify potential cancer treatments.
Researchers found that certain antibodies can reduce antitumor immune cells, highlighting the need to consider ADCC activity when designing or selecting ICI therapeutics. This study could help improve cancer treatment by engineering antibodies that avoid damaging essential immune cells.